Менопаузальная гормональная терапия: курс на повышение эффективности


Цитировать

Полный текст

Аннотация

Настоящая публикация посвящена одному из наиболее актуальных направлений гинекологической практики - менопаузальной гормональной терапии. Информация представлена в виде аналитического обзора международных исследований в отношении преимуществ и рисков менопаузальной гормональной терапии. Учитывая быстрый рост числа женщин в среднем и зрелом возрасте, крайне важно выявление преимуществ и рисков менопаузальной терапии с целью оптимизации качества жизни и долгосрочного благополучия.

Об авторах

Ара Леонидович Унанян

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

Email: 9603526@mail.ru
д-р мед. наук, проф. каф. акушерства и гинекологии №1 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2

Ираида Степановна Сидорова

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

акад. РАН, д-р мед. наук, проф. каф. акушерства и гинекологии №1 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2

Лиана Назимовна Аминова

КБ №2 МЕДСИ

канд. мед. наук, глав. специалист по гинекологии, зав. отд-нием гинекологии КБ №2 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 5

Владимир Александрович Алимов

КБ №2 МЕДСИ

акушер-гинеколог отд-ния гинекологии 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 5

Анастасия Дмитриевна Никонец

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

Центр инновационных образовательных программ «Медицина будущего» 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2

Юрий Васильевич Чушков

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

канд. мед. наук, доц. каф. акушерства и гинекологии №1 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2

Анастасия Викторовна Щукина

ГБУЗ ГП №68

зав. женской консультацией 119180, Russian Federation, Moscow, ul. Malaya Yakimanka, d. 22, str. 1

Дмитрий Валерьевич Бабурин

ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»

ассистент каф. акушерства и гинекологии №1 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2

Список литературы

  1. Lobo R.A, Davis S.R, de Villiers T.J. et al. Prevention of diseases after menopause. Climacteric 2014; 17: 540-56.
  2. Baber R.J, Panay N, Fenton A; IMS Writing Group (2016). IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016; 19 (2): 109-50.
  3. Harlow S.D, Gass M, Hall J.E. et al; STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10:addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97 (4): 1159-68. doi: 10.1210/jc.2011-3362
  4. Abdulnour J, Doucet E, Brochu M et al. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause 2012;19 (7): 760-7.
  5. Dubnov-Raz G, Pines A, Berry E.M. Diet and lifestyle in managing postmenopausal obesity. Climacteric 2007; 10 (Suppl. 2): 38-41.
  6. Luoto R, Moilanen J, Heinonen R et al. Effect of aerobic training on hot flushes and quality of life - a randomized controlled trial. Ann Med 2012; 44: 616-26.
  7. Goodpaster B.H, Park S.W, Harris T.B. et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006; 61: 1059-64.
  8. Grindler N.M, Santoro N.F. Menopause and exercise. Menopause 2015;22 (12): 1351-8. doi: 10.1097/GME.0000000000000536
  9. Chen Z, Bassford T, Green S.B. et al. Postmenopausal hormone therapy and body composition - a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 2005; 82 (3): 651-6.
  10. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int 2013; 19 (4): 155-62.
  11. Cody J.D, Jacobs M.L, Richardson K.et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405. doi: 10.1002/14651858.CD001405.pub3
  12. Moore K, Dumoulin C, Bradley C et al. Adult conservative management.In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris:Health Publications Ltd, 2013; p. 1101-228.
  13. Villiers T.J. Bone health and osteoporosis in postmenopausal women.Best Pract Res Clin Obstet Gynaecol 2009; 23: 73-85.
  14. Lindsay R, Silverman S.L, Cooper C. et al. Risk of new vertebral fracture in the year following fracture. JAMA 2001; 285: 320-3.
  15. Karsdal M.A, Bay-Jensen A.C, Henriksen K, Christiansen C. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation:may estrogen be a magic bullet? Menopause Int 2012; 18: 139-46.
  16. Welton A.J, Vickers M.R, Kim J. et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337: 550-3.
  17. Cirillo D.J, Wallace R.B, Wu L, Yood R.A. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum 2006; 54: 3194-204.
  18. Masuda Y, Hirao T, Mizunuma H. Improvement of skin surface texture by topical estradiol treatment in climacteric women. J Dermatol Treat 2013; 24: 312-17.
  19. Verdier-Se´vrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric 2007; 10:289-97.
  20. Maruthur N.M, Wang N-Y, Appel L.J. Lifestyle interventions reduce coronary artery disease risk. Results from the PREMIER trial. Circulation 2009; 119: 2026-31.
  21. Hodis H.N, Collins P. Mack W.J. et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15: 217-28.
  22. Lethbridge-Вejku M, Vickerie J. Summary Health Statistics for U.S.Adults: National Health Interview Survey, 2003. Vital Health Stat 2005;10: 225.
  23. Lisabeth L.D, Beiser A.S, Brown D.L. et al. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 2009; 40:1044-9.
  24. Rocca W.A, Grossardt B.R, Miller V.M. et al. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012; 19(3): 272-7. doi: 10.1097/gme.0b013e31822a9937
  25. Henderson V.W, Lobo R.A. Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 2012; 15: 229-34.
  26. Lobo R.A, Clarkson T.B. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011; 18: 237-40.
  27. Laliberté F, Dea K, Duh M.S. et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism?Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052-9.
  28. Scarabin P.Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res 2014; 43: 21-32.
  29. Curb J.D, Prentice R.L, Bray P.F. et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166: 772-80.
  30. Manson J.E, Chlebowski R.T, Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
  31. Smith N.L, Blondon M, Wiggins K.L. et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 2014; 174:25-31.
  32. Olie V, Plu-Bureau G, Conard J et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011; 18: 488-93.
  33. Canonico M, Oger E, Conard J et al. EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboem bolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4: 1259-65.
  34. Cushman M, Kuller L.H, Prentice R. et al. Women’s Health Initiative Investigators.Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-80.
  35. Canonico M, Plu-Bureau G, Lowe G.D, Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227-31.
  36. Straczek C, Oger E, Yon de Jonage-Canonico M.B. et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495-500.
  37. Blondon M, Van Hylckama Vlieg A, Wiggins K.L. et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost 2014; 12: 879-86.
  38. Canonico M, Fournier A, Carcaillon L et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340-5.
  39. Henderson V.W, Sherwin B.B. Surgical versus natural menopause: cognitive issues. Menopause 2007; 14: 572-9.
  40. Chlebowski R.T, Hendrix S.L, Langer R.D. et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003; 289: 3243-53.
  41. Anderson G.L, Chlebowski R.T, Rossouw J.E. et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103-15.
  42. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrelreleasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060-6.
  43. Anderson G.L., Chlebowski R.T., Aragaki A.K. et al. Conjugated equine o estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-86.
  44. Lundstrom E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717-22.
  45. Kenemans P, Bundred N.J, Foidart J.M. et al. LIBERATE Study Group. Safety and efficacy of tibolone in breastcancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-46.
  46. Gupta J.K, Chien P.F, Voit D. et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002;81: 799-816.
  47. Weiderpass E, Adami H.O, Baron J.A. et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131-7.
  48. Somboonporn W, Panna S, Temtanakitpaisan T et al. Effects of the levonorgestrel releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18: 1060-6.
  49. Weber R, Brenck J, Diener H.C. Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol 2012; 210: 519-46.
  50. Massaro M, Scoditti E, Carluccio M.A. et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost 2013; 109 (2): 280-9.
  51. Chen Y.C, Chen C.H, Ko W. et al. Dipyridamole inhibits lipopolysaccharideinduced cyclooxygenase-2 and monocyte chemoattractant protein1 via heme oxygenase-1-mediated reactive oxygen species reduction in rat mesangial cells. Eur J Pharmacol 2011; 650 (1):445-50.
  52. Eisert W.G. Dipyridamole in antithrombotic treatment. Adv Cardiol2012; 47: 78-86.
  53. Ge S.M, Zhan D.L, Zhang S.H. et al. Reverse screening approach to identify potential anti-cancer targets of dipyridamole. Am J Transl Res. 2016; 8(12): 5187-98. eCollection 2016.
  54. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9):822-9
  55. Goda A.E, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435-45.
  56. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis Mol Carcinog 2014; 53 (3): 243-52.
  57. Balakumar P, Nyo Y.H, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144-50.
  58. Инструкции по медицинскому применению препаратов Курантил® N25(ПN013897/01-280312), Курантил® N75(ПN013899/01-280312).

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).